Dec 7 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS ENTERS INTO SEPARATE PRIVATELY NEGOTIATED AGREEMENTS WITH CERTAIN HOLDERS OF ITS CONVERTIBLE NOTES.ANI PHARMACEUTICALS-ENTERED INTO SEPARATE, PRIVATELY NEGOTIATED AGREEMENTS WITH CERTAIN HOLDERS OF OUTSTANDING 3.00% CONVERTIBLE SENIOR NOTES DUE 2019.ANI PHARMACEUTICALS INC - AGREED TO REPURCHASE $25.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES FOR A TOTAL OF $26.1 MILLION IN CASH.ANI PHARMACEUTICALS INC - ANI HAS ALSO ENTERED INTO AN AGREEMENT WITH DEALER PARTY TO CERTAIN CONVERTIBLE NOTE HEDGE TRANSACTIONS.ANI PHARMACEUTICALS INC - ALSO ENTERED INTO AGREEMENTS WITH SUCH DEALER COUNTERPARTY TO UNWIND CERTAIN WARRANT TRANSACTIONS.
Full Article
April 18 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS ANNOUNCES APPROVAL OF MORPHINE SULFATE ORAL SOLUTION.ANI PHARMACEUTICALS INC - RECEIVED APPROVAL FROM U.S. FDA OF ITS ANDA FOR MORPHINE SULFATE ORAL SOLUTION 10MG/5ML, 20MG/5ML AND 100MG/5ML.
Full Article
Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ENTERS FIVE-YEAR $125 MILLION SENIOR SECURED CREDIT FACILITY WITH CITIZENS BANK.ANI PHARMACEUTICALS SAYS FACILITY ALSO INCLUDES A $50 MILLION SENIOR SECURED REVOLVING CREDIT FACILITY WHICH REMAINS UN-DRAWN.ANI PHARMA SAYS TERM LOAN ALSO USED TO REFINANCE EXISTING INDEBTEDNESS OF $25 MILLION.
Full Article
Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION.ANI PHARMACEUTICALS INC - ACQUISITIONS WERE FUNDED THROUGH A COMBINATION OF CASH AND DEBT.ANI PHARMACEUTICALS SAYS ADDITION OF ASSETS WILL BE MATERIAL TO REVENUE AND EBITDA IN 2018.
Full Article
Nov 2 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance.Q3 adjusted Non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $0.40.Q3 revenue $48.2 million versus I/B/E/S view $48.1 million.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc sees for full year 2017 net revenues $181 million to $183 million.ANI Pharmaceuticals Inc sees for full year 2017 adjusted Non-GAAP diluted earnings per share $3.83 to $4.00.Q3 earnings per share view $0.99, revenue view $48.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.84, revenue view $182.1 million -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc - ANI intends to request a meeting with fda in Q4 of 2017 to present its regulatory filing plan.
Full Article
Ani Pharmaceuticals Inc : Ani pharmaceuticals acquires inderal® xl and innopran xl® . Ani pharmaceuticals inc - acquisitions were funded through a combination of cash and debt . Ani pharma - has begun selling inderal xl 80mg, 120mg sustained release capsules, innopran xl 80mg, 120mg sustained release capsules under current labels . Ani pharma - will transition inderal xl and innopran xl to ani label at a future date . Ani pharmaceuticals inc - acquired inderal xl from cranford pharmaceuticals, llc and innopran xl from holmdel pharmaceuticals lp .Ani pharmaceuticals inc- acquired inderal xl from cranford pharmaceuticals, llc and innopran xlfrom holmdel pharmaceuticals lp.
Full Article
Earnings vs. 
Estimates